Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis in hospitalised patients

被引：0
作者：
R Launois
L Riou Franca
B Guidet
P Aegerter
X Huet
P Meshaka
P Pinton
机构：
[1] REES France,Biostatistique et Informatique médicale
[2] Réseau d'Evaluation en Economie de la Santé,undefined
[3] Hôpital Saint Antoine,undefined
[4] Hôpital Ambroise Paré,undefined
[5] Laboratoire Lilly France,undefined
来源：
Critical Care | / 6卷 / Suppl 1期
关键词：
Severe Sepsis; Cost Effectiveness Ratio; Expected Cost; Drotrecogin Alfa; Differential Cost;
D O I：
10.1186/cc1570
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
[31]   Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated) [J].
Andrew F Shorr ;
David R Nelson ;
Duncan LA Wyncoll ;
Konrad Reinhart ;
Frank Brunkhorst ;
George Matthew Vail ;
Jonathan Janes .
Critical Care, 12
[32]   Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis [J].
Ely, EW ;
Laterre, PF ;
Angus, DC ;
Helterbrand, JD ;
Levy, H ;
Dhainaut, JF ;
Vincent, JL ;
Macias, WL ;
Bernard, GR .
CRITICAL CARE MEDICINE, 2003, 31 (01) :12-19
[33]   Obesity does not alter the pharmacokinetics of drotrecogin alfa (activated) in severe sepsis [J].
Levy, H ;
Small, D ;
Heiselman, DE ;
Riker, R ;
Steingrub, J ;
Chen, RQ ;
Qualy, RL ;
Darstein, C ;
Mongan, E .
ANNALS OF PHARMACOTHERAPY, 2005, 39 (02) :262-267
[34]   Safety of drotrecogin alfa (activated) treatment in patients with severe sepsis on renal replacement therapy without additional anticoagulation [J].
L Mirea ;
I Luca Vasiliu ;
R Ungureanu ;
A Balanescu ;
I Grintescu .
Critical Care, 15 (Suppl 1)
[35]   Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis [J].
Jean-Louis Vincent ;
James O'Brien ;
Arthur Wheeler ;
Xavier Wittebole ;
Rekha Garg ;
Benjamin L Trzaskoma ;
David P Sundin .
Critical Care, 10
[36]   Benefit-Risk Assessment of Drotrecogin Alfa (Activated) in the Treatment of Sepsis [J].
Daniel De Backer .
Drug Safety, 2007, 30 :995-1010
[37]   An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures [J].
Madeline Betancourt ;
Peggy S. McKinnon ;
R. Michael Massanari ;
Salmaan Kanji ;
David Bach ;
John W. Devlin .
PharmacoEconomics, 2003, 21 :1331-1340
[38]   Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions [J].
Gentry, Chris A. ;
Gross, Kristin Busse ;
Sud, Bhanu ;
Drevets, Douglas A. .
CRITICAL CARE MEDICINE, 2009, 37 (01) :19-25
[39]   How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design [J].
Kalil, Andre C. ;
Sun, Junfeng .
INTENSIVE CARE MEDICINE, 2008, 34 (10) :1804-1811
[40]   Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis [J].
Pierre-François Laterre ;
William L Macias ;
Jonathan Janes ;
Mark D Williams ;
David R Nelson ;
Amand RJ Girbes ;
Jean-François Dhainaut ;
Edward Abraham .
Critical Care, 12
12345